InvestorsHub Logo
Followers 505
Posts 6242
Boards Moderated 0
Alias Born 09/20/2006

Re: None

Tuesday, 03/14/2017 9:43:42 AM

Tuesday, March 14, 2017 9:43:42 AM

Post# of 34618
TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

Collaborators at Mayo Clinic Secure New $3.7 Million Grant from U.S. Department of DefenseSecond TapImmune T-cell vaccine candidate to be tested in a DoD-funded study

http://www.marketwatch.com/story/tapimmune-announces-fully-funded-phase-2-clinical-study-of-her2-targeted-vaccine-in-early-breast-cancer-2017-03-14

Investor 100
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News